CSL Limited (English Wikipedia)

Robin, A. De Q. Penfold, William James (1875–1941). Canberra: National Centre of Biography, Australian National University.
Egan, Bryan, "Morgan, Frederick Grantley (1891–1969)", Australian Dictionary of Biography, Canberra: National Centre of Biography, Australian National University, retrieved 22 September 2020
Gardiner, Lyndsay; Serle, Geoffrey (2000). "Keogh, Esmond Venner (Bill) (1895–1970)". Australian Dictionary of Biography. 15. National Centre of Biography, Australian National University.

archive.today

"CSL LTD (CSL:ASX): Stock Quote & Company Profile". Bloomberg Businessweek. Archived from the original on 18 January 2013. Retrieved 13 August 2012.

asx.com.au

"CSL Limited". Australian Securities Exchange. Retrieved 7 February 2020.

businessweek.com

investing.businessweek.com

"CSL LTD (CSL:ASX): Stock Quote & Company Profile". Bloomberg Businessweek. Archived from the original on 18 January 2013. Retrieved 13 August 2012.

csl.com

investors.csl.com

"CSL Annual Report 2021/22". CSL Limited. April 2022. Retrieved 29 March 2023.
"CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform" (Press release). CSL. 6 August 2017. Retrieved 15 December 2021.
"CSL to Acquire Biotech Company Vitaeris" (Press release). CSL. 6 September 2020. Retrieved 15 December 2021.

csl.com

"Annual Report 2019" (PDF). CSL Limited. 2019.
"CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia". csl.com. 7 September 2020. Retrieved 7 September 2020.

csl.com.au

Sequirus Commonwealth Serum Laboratories
"Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration". Melbourne, Australia: CSL Limited. 18 September 2009. Archived from the original on 25 September 2009. Retrieved 26 September 2009. CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 2009 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over.
"CSL wins equal opportunity award for onsite childcare centre". CSL Newsroom. CSL. Retrieved 25 October 2016.

cslbehring.com.au

"Products". cslbehring.com.au. Retrieved 7 February 2020.

doi.org

Hobbins, Peter G.; Winkel, Kenneth D. (3 December 2007). "The forgotten successes and sacrifices of Charles Kellaway, director of the Walter and Eliza Hall Institute, 1923–1944". The Medical Journal of Australia. 187 (11): 645–648. doi:10.5694/j.1326-5377.2007.tb01457.x. PMID 18072902. S2CID 23444263.
Kelly, Heath A; Skowronski, Danuta M; De Serres, Gaston; Effler, Paul V (19 September 2011). "Adverse events associated with 2010 CSL and other inactivated influenza vaccines". The Medical Journal of Australia. 195 (6): 318–320. doi:10.5694/mja11.10941. PMID 21929484. S2CID 9389146.

fiercepharma.com

Coey, Sharon Klahr (26 August 2022). "CSL to unite all business units, including Seqirus, under the CSL umbrella". Fierce Pharma. Archived from the original on 26 August 2022.

genengnews.com

Phillipidis, Alex (27 October 2014). "Novartis Selling Flu Vaccine Business to CSL for $275M". Genetic Engineering & Biotechnology News. Retrieved 22 May 2020.

health.gov.au

www1.health.gov.au

Flood, Phillip; Wills, Peter; Lawler, Peter; Ryan, Graeme; Rickard, Kevin A. (2006). Review of Australia's Plasma Fractionation Arrangements (PDF). ISBN 1-74186-121-7.

mja.com.au

Hobbins, Peter G.; Winkel, Kenneth D. (3 December 2007). "The forgotten successes and sacrifices of Charles Kellaway, director of the Walter and Eliza Hall Institute, 1923–1944". The Medical Journal of Australia. 187 (11): 645–648. doi:10.5694/j.1326-5377.2007.tb01457.x. PMID 18072902. S2CID 23444263.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hobbins, Peter G.; Winkel, Kenneth D. (3 December 2007). "The forgotten successes and sacrifices of Charles Kellaway, director of the Walter and Eliza Hall Institute, 1923–1944". The Medical Journal of Australia. 187 (11): 645–648. doi:10.5694/j.1326-5377.2007.tb01457.x. PMID 18072902. S2CID 23444263.
Kelly, Heath A; Skowronski, Danuta M; De Serres, Gaston; Effler, Paul V (19 September 2011). "Adverse events associated with 2010 CSL and other inactivated influenza vaccines". The Medical Journal of Australia. 195 (6): 318–320. doi:10.5694/mja11.10941. PMID 21929484. S2CID 9389146.

nla.gov.au

"BUNDABERG TRAGEDY, Daily Examiner". 14 June 1928. p. 3 – via Trove.
"SAFER FIRST AID, Papua New Guinea Post-Courier". 18 April 1979. p. 11 – via Trove.
"New test for snake bites, The Canberra Times". 30 October 1979. p. 14 – via Trove.

trove.nla.gov.au

"Trove". trove.nla.gov.au. Retrieved 22 September 2020.

pm.gov.au

"Australia secures onshore manufacturing agreements for two COVID-19 vaccines | Prime Minister of Australia". pm.gov.au. 7 September 2020. Archived from the original on 7 September 2020. Retrieved 7 September 2020.

questap.com.au

"CSL bursts through the $100 barrier". Quest Asset Partners. 4 August 2015. Archived from the original on 28 February 2016. Retrieved 22 February 2021.

reuters.com

Nainan, Nikhil; Koltrowitz, Silke; Murdoch, Scott (14 December 2021). "Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln". Reuters. Retrieved 15 December 2021.

semanticscholar.org

api.semanticscholar.org

Hobbins, Peter G.; Winkel, Kenneth D. (3 December 2007). "The forgotten successes and sacrifices of Charles Kellaway, director of the Walter and Eliza Hall Institute, 1923–1944". The Medical Journal of Australia. 187 (11): 645–648. doi:10.5694/j.1326-5377.2007.tb01457.x. PMID 18072902. S2CID 23444263.
Kelly, Heath A; Skowronski, Danuta M; De Serres, Gaston; Effler, Paul V (19 September 2011). "Adverse events associated with 2010 CSL and other inactivated influenza vaccines". The Medical Journal of Australia. 195 (6): 318–320. doi:10.5694/mja11.10941. PMID 21929484. S2CID 9389146.

seqirus.com

"Products". Seqirus. 6 December 2018. Retrieved 5 February 2020.

seqirus.com.au

"Products". Seqirus. Australia. Retrieved 9 February 2020.

tga.gov.au

Administration, Australian Government Department of Health Therapeutic Goods (28 September 2010). "Analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL)". Therapeutic Goods Administration (TGA). Retrieved 25 July 2022.

theguardian.com

Tran, Mark (22 July 2009). "First human trials of swine flu vaccine begin in Australia". The Guardian. ISSN 0261-3077. Retrieved 7 September 2020.

thepharmaletter.com

"Aventis disposes of Behring unit with $925M sale to Australia's CSL –". thepharmaletter.com. The Pharma Letter. 15 December 2003. Archived from the original on 23 September 2021. Retrieved 22 February 2021. … Aventis says that it has agreed to sell its Aventis Behring blood products business to Australia's CSL …

uniquest.com.au

"A global solution to reducing cervical cancer" (PDF). Uniquest commercialisation stories. The University of Queensland. Retrieved 29 April 2016.

washingtonpost.com

Willman, David (15 March 2020). "Federal vaccine development sites ill-suited to counter covid-19 epidemic". The Washington Post. Retrieved 15 March 2020.

web.archive.org

"Aventis disposes of Behring unit with $925M sale to Australia's CSL –". thepharmaletter.com. The Pharma Letter. 15 December 2003. Archived from the original on 23 September 2021. Retrieved 22 February 2021. … Aventis says that it has agreed to sell its Aventis Behring blood products business to Australia's CSL …
"CSL bursts through the $100 barrier". Quest Asset Partners. 4 August 2015. Archived from the original on 28 February 2016. Retrieved 22 February 2021.
Coey, Sharon Klahr (26 August 2022). "CSL to unite all business units, including Seqirus, under the CSL umbrella". Fierce Pharma. Archived from the original on 26 August 2022.
"Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration". Melbourne, Australia: CSL Limited. 18 September 2009. Archived from the original on 25 September 2009. Retrieved 26 September 2009. CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 2009 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over.
"Australia secures onshore manufacturing agreements for two COVID-19 vaccines | Prime Minister of Australia". pm.gov.au. 7 September 2020. Archived from the original on 7 September 2020. Retrieved 7 September 2020.
"Update on The University of Queensland COVID-19 vaccine" (PDF). CSL Limited. Archived (PDF) from the original on 11 December 2020.
Global product portfolio CSL Behring, 3 November 2010

weblink.com.au

wcsecure.weblink.com.au

"Update on The University of Queensland COVID-19 vaccine" (PDF). CSL Limited. Archived (PDF) from the original on 11 December 2020.

worldcat.org

search.worldcat.org

Tran, Mark (22 July 2009). "First human trials of swine flu vaccine begin in Australia". The Guardian. ISSN 0261-3077. Retrieved 7 September 2020.

wsj.com

Dow Jones Newswires (9 December 2003). "Australia's CSL Agrees to Acquire Aventis Unit for up to $925 Million". The Wall Street Journal. Retrieved 22 February 2021. … this deal eclipses the A$1 billion (US$740.2 million) CSL spent in 2000 to buy ZLB Bioplasma from the Swiss Red Cross.